RE:RE:x sites, y patients, always underwhelming Totally agree.
Stoppage possibility once results are published.
(small correction - this is not at midpoint but 90 of 150 (=60%). Or if you include Euphrates patients that met the Tigris criteria ( which is called for) more like > 80% complete.
But you are also correct that the "confirmation" in this "open" Trial could become compelling at 100, 110 or 120 requiring any keen observer including the FDA, to draw an inescapable conclusion at any time after 90.
Finally there is every possibility that the FDA or that Spectral insists on achieving the full 150 ... however...
... there is nothing that says that Baxter won't pull the trigger having drawn their own conclusions about the inevitability of the final results after a deep dive post 90. At which point they could simply marshall the trial to the end themselves.
MM